|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glaser PE and Gross RW: Rapid
plasmenylethanolamine-selective fusion of membrane bilayers
catalyzed by an isoform of glyceraldehyde-3-phosphate
dehydrogenase: Discrimination between glycolytic and fusogenic
roles of individual isoforms. Biochemistry. 34:12193–12203. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tisdale EJ, Kelly C and Artalejo CR:
Glyceraldehyde-3-phosphate dehydrogenase interacts with Rab2 and
plays an essential role in endoplasmic reticulum to Golgi transport
exclusive of its glycolytic activity. J Biol Chem. 279:54046–54052.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hara MR and Snyder SH: Nitric
oxide-GAPDH-Siah: A novel cell death cascade. Cell Mol Neurobiol.
26:527–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baxi MD and Vishwanatha JK: Uracil
DNA-glycosylase/glyceraldehyde-3-phosphate dehydrogenase is an Ap4A
binding protein. Biochemistry. 34:9700–9707. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng L, Roeder RG and Luo Y: S phase
activation of the histone H2B promoter by OCA-S, a coactivator
complex that contains GAPDH as a key component. Cell. 114:255–266.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barroso I, Benito B, Garcí-Jiménez C,
Hernández A, Obregón MJ and Santisteban P: Norepinephrine,
tri-iodothyronine and insulin upregulate glyceraldehyde-3-phosphate
dehydrogenase mRNA during Brown adipocyte differentiation. Eur J
Endocrinol. 141:169–179. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valenti MT, Bertoldo F, Dalle Carbonare L,
Azzarello G, Zenari S, Zanatta M, Balducci E, Vinante O and Lo
Cascio V: The effect of bisphosphonates on gene expression: GAPDH
as a housekeeping or a new target gene? BMC Cancer. 6:492006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sikand K, Singh J, Ebron JS and Shukla GC:
Housekeeping gene selection advisory: Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and β-actin are targets of miR-644a. PLoS
One. 7:e475102012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bjerregaard H, Pedersen S, Kristensen SR
and Marcussen N: Reference genes for gene expression analysis by
real-time reverse transcription polymerase chain reaction of renal
cell carcinoma. Diagn Mol Pathol. 20:212–217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma Y, Dai H, Kong X and Wang L: Impact of
thawing on reference gene expression stability in renal cell
carcinoma samples. Diagn Mol Pathol. 21:157–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Majidzadeh-A K, Esmaeili R and Abdoli N:
TFRC and ACTB as the best reference genes to quantify Urokinase
plasminogen activator in breast cancer. BMC Res Notes. 4:2152011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo Y, Chen JX, Yang S, Fu XP, Zhang Z,
Chen KH, Huang Y, Li Y, Xie Y and Mao YM: Selection of reliable
reference genes for gene expression study in nasopharyngeal
carcinoma. Acta Pharmacol Sin. 31:1487–1494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stratton MR: Exploring the genomes of
cancer cells: Progress and promise. Science. 331:1553–1558. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nicoloso MS, Sun H, Spizzo R, Kim H,
Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L,
et al: Single-nucleotide polymorphisms inside microRNA target sites
influence tumor susceptibility. Cancer Res. 70:2789–2798. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Du X, Zhou Z, Jiang J, Zhang Z, Ye
L and Hong H: A gain-of-function ACTC1 3′UTR mutation that
introduces a miR-139-5p target site may be associated with a
dominant familial atrial septal defect. Sci Rep. 6:254042016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Flynt AS and Lai EC: Biological principles
of microRNA-mediated regulation: Shared themes amid diversity. Nat
Rev Genet. 9:831–842. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang L, Du WW, Yang X, Chen K, Ghanekar A,
Levy G, Yang W, Yee AJ, Lu WY, Xuan JW, et al: Versican
3′-untranslated region (3′-UTR) functions as a ceRNA in inducing
the development of hepatocellular carcinoma by regulating miRNA
activity. FASEB J. 27:907–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Karreth FA, Tay Y, Perna D, Ala U, Tan SM,
Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, et al:
In vivo identification of tumor-suppressive PTEN ceRNAs in an
oncogenic BRAF-induced mouse model of melanoma. Cell. 147:382–395.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee DY, Shatseva T, Jeyapalan Z, Du WW,
Deng Z and Yang BB: A 3′-untranslated region (3′UTR) induces organ
adhesion by regulating miR-199a* functions. PLoS One. 4:e45272009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer
A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J
and Califano A: An extensive microRNA-mediated network of RNA-RNA
interactions regulates established oncogenic pathways in
glioblastoma. Cell. 147:370–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stahlhut C and Slack FJ: MicroRNAs and the
cancer phenotype: Profiling, signatures and clinical implications.
Genome Med. 5:1112013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li YL, Ye F, Hu Y, Lu WG and Xie X:
Identification of suitable reference genes for gene expression
studies of human serous ovarian cancer by real-time polymerase
chain reaction. Anal Biochem. 394:110–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Yu H, Ye L, Jin L, Yu M and Lv Y:
Integrated regulatory mechanisms of miRNAs and targeted genes
involved in colorectal cancer. Int J Clin Exp Pathol. 8:517–529.
2015.PubMed/NCBI
|
|
31
|
Jeggari A, Marks DS and Larsson E:
miRcode: A map of putative microRNA target sites in the long
non-coding transcriptome. Bioinformatics. 28:2062–2063. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rehmsmeier M, Steffen P, Hochsmann M and
Giegerich R: Fast and effective prediction of microRNA/target
duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ying X, Wei K, Lin Z, Cui Y, Ding J, Chen
Y and Xu B: MicroRNA-125b suppresses ovarian cancer progression via
suppression of the epithelial-mesenchymal transition pathway by
targeting the SET protein. Cell Physiol Biochem. 39:501–510. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vriens MR, Weng J, Suh I, Huynh N,
Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E: MicroRNA
expression profiling is a potential diagnostic tool for thyroid
cancer. Cancer. 118:3426–3432. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jia HY, Wang YX, Yan WT, Li HY, Tian YZ,
Wang SM and Zhao HL: MicroRNA-125b functions as a tumor suppressor
in hepatocellular carcinoma cells. Int J Mol Sci. 13:8762–8774.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Henson BJ, Bhattacharjee S, O'Dee DM,
Feingold E and Gollin SM: Decreased expression of miR-125b and
miR-100 in oral cancer cells contributes to malignancy. Genes
Chromosomes Cancer. 48:569–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meister G, Landthaler M, Patkaniowska A,
Dorsett Y, Teng G and Tuschl T: Human Argonaute2 mediates RNA
cleavage targeted by miRNAs and siRNAs. Mol Cell. 15:185–197. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saini U, Naidu S, ElNaggar AC, Bid HK,
Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P,
et al: Elevated STAT3 expression in ovarian cancer ascites promotes
invasion and metastasis: A potential therapeutic target. Oncogene.
36:168–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wen W, Liang W, Wu J, Kowolik CM, Buettner
R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, et al: Targeting
JAK1/STAT3 signaling suppresses tumor progression and metastasis in
a peritoneal model of human ovarian cancer. Mol Cancer Ther.
13:3037–3048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Boehm JS and Hahn WC: Towards systematic
functional characterization of cancer genomes. Nat Rev Genet.
12:487–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chin L, Andersen JN and Futreal PA: Cancer
genomics: From discovery science to personalized medicine. Nat Med.
17:297–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu W, Wu L, Zhu M, Wang Z, Wu M, Li P, Nie
Y, Lin X, Hu J, Eskilsson E, et al: miRNA mediated noise making of
3′UTR mutations in cancer. Genes (Basel). 9(pii): E5452018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lopes-Ramos CM, Barros BP, Koyama FC,
Carpinetti PA, Pezuk J, Doimo NTS, Habr-Gama A, Perez RO and
Parmigiani RB: E2F1 somatic mutation within miRNA target site
impairs gene regulation in colorectal cancer. PLoS One.
12:e01811532017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Veerla S, Lindgren D, Kvist A, Frigyesi A,
Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, et
al: MiRNA expression in urothelial carcinomas: Important roles of
miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and
metastasis, and frequent homozygous losses of miR-31. Int J Cancer.
124:2236–2242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alpini G, Glaser SS, Zhang JP, Francis H,
Han Y, Gong J, Stokes A, Francis T, Hughart N, Hubble L, et al:
Regulation of placenta growth factor by microRNA-125b in
hepatocellular cancer. J Hepatol. 55:1339–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST,
Nan X, Cao N, Fu CJ, Yan XL, Jia YL, et al: MicroRNA-125b
attenuates epithelial-mesenchymal transitions and targets stem-like
liver cancer cells through small mothers against decapentaplegic 2
and 4. Hepatology. 62:801–815. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Han Y, Liu Y, Zhang H, Wang T, Diao R,
Jiang Z, Gui Y and Cai Z: Hsa-miR-125b suppresses bladder cancer
development by down-regulating oncogene SIRT7 and oncogenic long
non-coding RNA MALAT1. FEBS Lett. 587:3875–3882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu N, Zhang L, Meisgen F, Harada M,
Heilborn J, Homey B, Grandér D, Ståhle M, Sonkoly E and Pivarcsi A:
MicroRNA-125b down-regulates matrix metallopeptidase 13 and
inhibits cutaneous squamous cell carcinoma cell proliferation,
migration, and invasion. J Biol Chem. 287:29899–29908. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tay Y, Kats L, Salmena L, Weiss D, Tan SM,
Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al:
Coding-independent regulation of the tumor suppressor PTEN by
competing endogenous mRNAs. Cell. 147:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Poliseno L, Salmena L, Zhang J, Carver B,
Haveman WJ and Pandolfi PP: A coding-independent function of gene
and pseudogene mRNAs regulates tumour biology. Nature.
465:1033–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jin XJ, Chen XJ, Zhang ZF, Hu WS, Ou RY,
Li S, Xue JS, Chen LL, Hu Y and Zhu H: Long noncoding RNA SNHG12
promotes the progression of cervical cancer via modulating
miR-125b/STAT3 axis. J Cell Physiol. 234:6624–6632. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu LH, Li H, Li JP, Zhong H, Zhang HC,
Chen J and Xiao T: miR-125b suppresses the proliferation and
migration of osteosarcoma cells through down-regulation of STAT3.
Biochem Biophys Res Commun. 416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Darnell JE: Validating Stat3 in cancer
therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Levy DE and Darnell JE Jr: Stats:
Transcriptional control and biological impact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
